MMRGlobal to Grant Royalty-Free Licenses to Universities to Research Ebola Therapies Using Company's Patented Monoclonal Antibody Technology

LOS ANGELES, CA--(Marketwired - Aug 5, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that the Company plans on granting royalty-free licenses to universities interested in using the Company's patented antibody technology for research and development into potential therapies in the fight against Ebola.

"In response to the humanitarian Ebola crisis, MMR plans on granting the licenses for research into the development of treatments for Ebola and other infectious diseases," said Robert H. Lorsch, MMRGlobal CEO.

MMRGlobal owns technology that allows for the development and use of therapeutics through production of specific monoclonal antibodies. The technology utilizes proprietary Human Framework Reassembly (HuFR) components in the construction of antibodies, which permits the antibodies to retain their beneficial properties while reducing or eliminating the side-effects seen with other antibodies that are due to the body's reaction to foreign substances.

MMRGlobal's biotech intellectual property portfolio includes patents granted in the United States, Australia, South Korea and Mexico directed to "Antibodies and Methods for Making and Using Them." Additional patents for the Company's antibody technology are also pending in the United States, Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and South Korea.

MMR's antibody technology has been used to produce anti-CD20 monoclonal antibodies having particular utility in fighting cancers. For additional information, contact Investor Relations at [e-mail].

About MMRGlobal Biotech Patents and Applications

MMRGlobal owns a portfolio of patents and patent applications for the monoclonal antibody technology, including patents and applications covering anti-CD20 antibodies and their production. U.S. Patent No. 8,465,741 protects various antibodies and the methods for making and using them; additional U.S. patent applications are pending. Foreign protection includes patents in Australia, South Korea and Mexico, along with pending applications in Brazil, Canada, China, Hong Kong, India, Europe, and Japan, all originating from international application PCT/US07/78568. The patents provide further detail of the development, structure, manufacture and established assays belonging to MMRGlobal.